Rofecoxib

@article{Hillson2000Rofecoxib,
  title={Rofecoxib},
  author={J. Hillson and D. Furst},
  journal={Expert Opinion on Pharmacotherapy},
  year={2000},
  volume={1},
  pages={1053 - 1066}
}
  • J. Hillson, D. Furst
  • Published 2000
  • Expert Opinion on Pharmacotherapy
  • Rofecoxib (Vioxx™, Merck & Co., Inc.) is a new orally-effective non-steroidal anti-inflammatory drug (NSAID) approved for treatment of acute pain, fever, primary dysmenorrhea and pain and inflammation in osteoarthritis (OA). It is also being evaluated for treatment of rheumatoid arthritis and adenomatous polyps of the colon. Rofecoxib is a specific inhibitor of cyclooxygenase-2 (COX-2), thereby inhibiting prostanoid synthesis in cells that express COX-2, including inflammatory cells. As cells… CONTINUE READING

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 68 REFERENCES
    Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
    • 690
    • Open Access
    Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo
    • 418
    • Open Access
    Cyclooxygenase‐2 inhibition by rofecoxib reverses naturally occurring fever in humans
    • 90